biote Corp. (NASDAQ:BTMD – Get Free Report) major shareholder Guines Llc acquired 750,000 shares of the business’s stock in a transaction dated Thursday, March 13th. The stock was acquired at an average cost of $3.22 per share, with a total value of $2,415,000.00. Following the completion of the transaction, the insider now owns 3,820,938 shares of the company’s stock, valued at approximately $12,303,420.36. The trade was a 24.42 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.
Guines Llc also recently made the following trade(s):
- On Monday, March 17th, Guines Llc purchased 100 shares of biote stock. The shares were purchased at an average cost of $3.74 per share, with a total value of $374.00.
biote Stock Performance
NASDAQ:BTMD traded up $0.24 during mid-day trading on Monday, hitting $4.00. 602,858 shares of the stock were exchanged, compared to its average volume of 174,311. The stock has a market capitalization of $217.35 million, a price-to-earnings ratio of 15.38 and a beta of 1.07. The firm’s 50-day simple moving average is $4.96 and its 200 day simple moving average is $5.55. biote Corp. has a fifty-two week low of $3.04 and a fifty-two week high of $8.44.
Hedge Funds Weigh In On biote
Analyst Ratings Changes
Separately, Craig Hallum dropped their price target on biote from $12.00 to $8.00 and set a “buy” rating for the company in a report on Thursday.
Read Our Latest Stock Analysis on biote
biote Company Profile
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.
Recommended Stories
- Five stocks we like better than biote
- Manufacturing Stocks Investing
- Can TikTok Stock Picks Really Make You Rich?
- Are Penny Stocks a Good Fit for Your Portfolio?
- The “Quality” Rotation: Back to Basics Investing
- The Most Important Warren Buffett Stock for Investors: His Own
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.